Finnish company Linio Biotech raises €4.2M investment round
Helsinki-based biotech growth company Linio Biotech has raised €4.2 million in a fresh investment round to help commercialise its injectable tissue product worldwide. The round brings the company’s total funding to over €9 million, EU-Startups reports.
- Linio Biotech was founded in 2017 by Timo Ylikomi, professor of cell biology, and cell biologist and researcher Riina Uusmies. The company develops an injectable tissue product called Tience. The product is intended for professional use only, as it helps skin naturally regenerate itself by accelerating the skin’s natural healing process.
- The current round was backed by new undisclosed Finnish private investors and doctors familiar with the industry. Previously, in the spring of 2023, Linio Biotech received a grant of almost $1 million from Business Finland for further development of its product.
- The fresh funding will help Linio Biotech expand the availability of its Tience product and treatments. The company is preparing for the commercial launch in the other Nordic countries.